Status
Conditions
Treatments
Study type
Funder types
Identifiers
About
A growing number of people in this country are overweight or obese. This is concerning as increasing weight has been shown to increase the risk of developing heart failure. However, there is also research to suggest that in people who already have heart failure, heavier people live longer. So, how does being overweight put a person at risk for heart failure, but once they have heart failure, protect them? There is no clear explanation for this dilemma.
People who are obese commonly have other diseases, such as high blood pressure, high cholesterol, and diabetes, that increase the risk of developing heart disease. It is this group of diseases that is referred to as "The Metabolic Syndrome." People with the metabolic syndrome also have increased levels of inflammation and clotting proteins in their blood stream. Current treatment of the metabolic syndrome involves using medications for cholesterol, blood pressure, and diabetes. Diet and exercise are also commonly recommended.
"Lifestyle intervention programs" are programs that help people lose weight by changing their eating habits and exercise / activity routines. Weight loss and exercise have been shown to lower the risk of developing diabetes and improve diabetes control, improve cholesterol abnormalities, and lower blood pressure. These programs have not previously included heart failure patients, however.
We hypothesize that using a lifestyle intervention program in addition to the usual medications for heart failure will result in improved symptoms of heart failure and control of the metabolic syndrome.
This study will be the first research study to look at the use of diet and exercise in treating heart failure patients who are overweight / obese with "the metabolic syndrome." The study will last 6 months. From this study we hope to learn whether diet and exercise is helpful in treating heart failure patients who are overweight. Specifically, the study will look at the short term effects on cardiac risk factors (blood pressure, cholesterol, blood sugar), heart failure symptoms, and exercise capacity.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Must meet 3 or more of the NCEP defined criteria for metabolic syndrome
Individuals with heart failure of ischemic or nonischemic etiologies * NYHA class II - III symptoms
Left ventricular ejection fraction less than 40%
Age 18-75 years
BMI greater than 25 kg/m2
Patients must have undergone a VO2 or exercise stress test within the last 6 months to exclude active ischemia or exercise-induced dysrhythmias
Exclusion criteria
NYHA IV or 6 minute walk less than 300 meters
Blood pressure greater than 160/100 mmHg
Patients undergoing active titration of their cardiac medications
Other comorbid illnesses which limit expected lifespan or affect the safety of interventions
Weight loss of more than 10 pounds of non-edematous body weight within the past 3 months
Pregnancy
HIV+, active tuberculosis or hepatitis C
Cancer requiring treatment within the past 5 years, unless the prognosis is excellent
Unstable angina, myocardial infarction, coronary artery bypass surgery, or angioplasty within the last 3 months
Angina with exertion
History of malignant arrythmias (Ventricular Tachycardia / Ventricular Fibrillation) without implanted defibrillator
Valvular heart disease:
Hypertrophic cardiomyopathy
Severe pulmonary hypertension with a pulmonary artery systolic pressure > 60 mmHg -
Aortic aneurysm (>6 cm in diameter)
Factors that may limit adherence to interventions or affect conduct of the trial
History of bariatric surgery
Chronic treatment with corticosteroids
Current diagnosis of schizophrenia, other psychotic disorder, or bipolar disorder
Current use of medications for weight loss
Inability to walk two blocks
Primary purpose
Allocation
Interventional model
Masking
20 participants in 2 patient groups
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal